Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Becker Muscular Dystrophy - Overview
Becker Muscular Dystrophy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Becker Muscular Dystrophy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Becker Muscular Dystrophy - Companies Involved in Therapeutics Development
ARMGO Pharma Inc
Edgewise Therapeutics Inc
Epirium Bio Inc
Italfarmaco SpA
Milo Biotechnology LLC
PhaseBio Pharmaceuticals Inc
Santhera Pharmaceuticals Holding AG
Sarcomed AB
Scholar Rock Inc
Stealth BioTherapeutics Corp
Tivorsan Pharmaceuticals Inc
Becker Muscular Dystrophy - Drug Profiles
apitegromab - Drug Profile
Product Description
Mechanism Of Action
History of Events
ARM-210 - Drug Profile
Product Description
Mechanism Of Action
History of Events
dextro epicatechin - Drug Profile
Product Description
Mechanism Of Action
History of Events
EDG-5506 - Drug Profile
Product Description
Mechanism Of Action
History of Events
elamipretide hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
epicatechin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene therapy To Activate Follistatin For Duchenne Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Becker Muscular Dystrophy And Inclusion Body Myositis - Drug Profile
Product Description
Mechanism Of Action
History of Events
givinostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
ndrolone decanoate - Drug Profile
Product Description
Mechanism Of Action
PB-1023 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TVN-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
vamorolone - Drug Profile
Product Description
Mechanism Of Action
History of Events
Becker Muscular Dystrophy - Dormant Projects
Becker Muscular Dystrophy - Discontinued Products
Becker Muscular Dystrophy - Product Development Milestones
Featured News & Press Releases
Apr 14, 2022: Edgewise-Funded tural history trial of Becker Muscular Dystrophy (BMD) now enrolling
Mar 08, 2022: Edgewise Therapeutics to present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference
Jan 05, 2022: Edgewise Therapeutics announces positive topline results from the EDG-5506 phase 1b clinical trial in adults with Becker Muscular Dystrophy (BMD)
Dec 15, 2021: Edgewise Therapeutics to report phase 1b topline results of EDG-5506 in individuals with Becker muscular dystrophy (BMD) on January 5, 2022, and initiates ARCH follow-on open label BMD study
Oct 28, 2021: Edgewise Therapeutics announces positive topline results from the EDG-5506 phase 1 multiple ascending dose (MAD) study in healthy volunteers (HVs) and doses first Becker Muscular Dystrophy (BMD) patients
Sep 27, 2021: ReveraGen and Santhera announce FDA orphan grant funding for clinical trial with vamorolone in Becker muscular dystrophy
Aug 16, 2021: Edgewise receives U.S. FDA Fast Track Desigtion for EDG-5506 for the treatment of individuals with Becker muscular dystrophy (BMD)
Jun 26, 2021: Italfarmaco announces topline data from phase 2 trial with Givinostat in patients with Becker Muscular Dystrophy
May 04, 2021: Edgewise Therapeutics announces publication of data demonstrating the elevation of fast but not slow skeletal muscle fiber injury biomarkers in the circulation of patients with Becker and Duchenne Muscular Dystrophy
Feb 22, 2021: Italfarmaco provides update on ongoing clinical programs with givinostat in oral presentation at XVIII Intertiol Conference on Duchenne and Becker Muscular Dystrophy
Nov 11, 2020: Edgewise Therapeutics initiates phase 1 clinical trial of EDG-5506 in Becker muscular dystrophy
Oct 29, 2020: Edgewise Therapeutics appoints John Moore as general counsel
Aug 12, 2020: Epirium Bio announces commencement of phase 1 clinical trial of EPM-01 in Becker muscular dystrophy
Apr 14, 2020: Epirium Bio receives FDA orphan-drug desigtion for EB 002 ((+)-Epicatechin) for the treatment of duchenne and becker muscular dystrophy
Jun 30, 2015: Cardero Therapeutics Presents at 2015 Parent Project Muscular Dystrophy Connect Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Becker Muscular Dystrophy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Becker Muscular Dystrophy, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Becker Muscular Dystrophy - Pipeline by ARMGO Pharma Inc, 2022
Becker Muscular Dystrophy - Pipeline by Edgewise Therapeutics Inc, 2022
Becker Muscular Dystrophy - Pipeline by Epirium Bio Inc, 2022
Becker Muscular Dystrophy - Pipeline by Italfarmaco SpA, 2022
Becker Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, 2022
Becker Muscular Dystrophy - Pipeline by PhaseBio Pharmaceuticals Inc, 2022
Becker Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, 2022
Becker Muscular Dystrophy - Pipeline by Sarcomed AB, 2022
Becker Muscular Dystrophy - Pipeline by Scholar Rock Inc, 2022
Becker Muscular Dystrophy - Pipeline by Stealth BioTherapeutics Corp, 2022
Becker Muscular Dystrophy - Pipeline by Tivorsan Pharmaceuticals Inc, 2022
Becker Muscular Dystrophy - Dormant Projects, 2022
Becker Muscular Dystrophy - Discontinued Products, 2022